Hengrui Medicine Enters into SHR7280 Licensing Agreement with Merck KGaA for €15 Million Upfront Payment

Hengrui Pharma: Signed a licensing agreement for the SHR7280 project with Merck KGaA, granting a paid license for the SHR7280 oral GnRH receptor antagonist project to Merck KGaA, with an upfront payment of 15 million euros.